RJFSA
FRTX

Raymond James Financial Services Advisors’s Fresh Tracks Therapeutics, Inc. Common Stock FRTX Stock Holding History

Raymond James Financial Services Advisors’s Portfolio FRTX Stock Details FRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-32
Closed -$24K – 2733
2017
Q3 		$24K Hold
32
– – ﹤0.01% 2496
2017
Q2 		$27K Hold
32
– – ﹤0.01% 2450
2017
Q1 		$23K Buy
+32
New +$22.6K ﹤0.01% 2361
2016
Q2 		– Sell
-12
Closed -$14K – 2343
2016
Q1 		$14K Buy
+12
New +$13.8K ﹤0.01% 2037

Other funds holding FRTX

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
AI
Ariel Investments Chicago, Illinois $8.93B AUM 29.58% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return

Raymond James Financial Services Advisors's FRTX Position: Q4 2017 in Review

Raymond James Financial Services Advisors sold out of Fresh Tracks Therapeutics, Inc. Common Stock (FRTX) in Q4 2017, closing a stake of 32 shares — an estimated $24K sold.

Raymond James Financial Services Advisors first reported a position in FRTX in Q1 2016 and held it in 4 quarters. The position peaked at $27K in Q2 2017. 31 funds tracked by Wall St. Rank hold FRTX as of Q4 2017.

  • Raymond James Financial Services Advisors reported no remaining Fresh Tracks Therapeutics, Inc. Common Stock position as of Q4 2017 after selling out during the quarter.
  • Raymond James Financial Services Advisors sold 32 Fresh Tracks Therapeutics, Inc. Common Stock shares in Q4 2017, an estimated $24K.
  • Raymond James Financial Services Advisors first reported a position in Fresh Tracks Therapeutics, Inc. Common Stock in Q1 2016 and held it in 4 quarters.
  • Raymond James Financial Services Advisors's Fresh Tracks Therapeutics, Inc. Common Stock position peaked at $27K in Q2 2017.
  • 31 funds tracked by Wall St. Rank held Fresh Tracks Therapeutics, Inc. Common Stock as of Q4 2017.

Based on Raymond James Financial Services Advisors's 13F filing for Q4 2017, filed 9 Feb 2018.